Mr. Greg Gubitz reports

HLS THERAPEUTICS REPORTS ANNUAL MEETING RESULTS

HLS Therapeutics Inc. has released the voting results from its annual meeting of shareholders held in a virtual format on June 16, 2023.

A total of 28,831,784 common shares, or 89.12 per cent of the total common shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as shown in the attached table.

HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the company's auditor with 28,796,380 votes (99.88 per cent) cast for and 35,404 votes (0.12 per cent) withheld.

Shareholders also approved certain proposed amendments to the corporation's stock option plan, and approved the unallocated options thereunder, with 23,405,117 votes (83.29 per cent) cast for and 4,694,371 votes (16.71 per cent) cast against.

About HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong record of success in these therapeutic areas and at managing products in each of these life cycle stages.